Bhang Soo-Young, Hwang Jun-Won, Kwak Young-Sook, Joung Yoo Sook, Lee Soyoung, Kim Bongseog, Sohn Seok Han, Chung Un Sun, Yang Jaewon, Hong Minha, Bahn Geon Ho, Choi Hyung Yun, Oh In-Hwan, Lee Yeon Jung
Department of Psychiatry, Eulji University School of Medicine, Eulji General Hospital, Seoul, Korea .
Department of Psychiatry, Kangwon National University School of Medicine, Chuncheon, Korea .
J Korean Med Sci. 2016 Aug;31(8):1284-91. doi: 10.3346/jkms.2016.31.8.1284. Epub 2016 Jun 7.
We evaluated the differences in utilization patterns including persistence and adherence among medications in children and adolescents with attention deficit hyperactivity disorder (ADHD). The current study was performed using data from the Korean Health Insurance Review and Assessment claims database from January 1, 2009 to December 31, 2013. Our study sample consisted of 10,343 children and adolescents with ADHD who were not given their newly prescribed medication in 360 days before the initial claim in 2010. Data were followed up from the initiation of treatment with ADHD medications in 2010 to December 31, 2013. Discontinuation rates for 4 ADHD medications in our sample ranged from 97.7% for immediate-release methylphenidate to 99.4% for atomoxetine using refill gap more than 30 days and from 56.7% for immediate-release methylphenidate to 62.3% for extended-release methylphenidate using refill gap more than 60 days. In the number of discontinued, we found significant differences among medications using refill gap more than 30 days. Among 4 ADHD medications, extended-release methylphenidate and atomoxetine had more days than immediate-release methylphenidate and osmotic-controlled oral delivery system methylphenidate. In logistic regression analyses, extended-release methylphenidate, osmotic-controlled oral delivery system methylphenidate, and atomoxetine showed less discontinuation compared to immediate-release methylphenidate group when a refill gap more than 30 days was used. In logistic regression analysis of adherence, we could not find any differences among 4 medication types. We suggest that the utilization patterns should be assessed regularly in order to improve future outcomes in children and adolescents with ADHD.
我们评估了患有注意力缺陷多动障碍(ADHD)的儿童和青少年在药物使用模式(包括持续性和依从性)方面的差异。本研究使用了韩国健康保险审查与评估理赔数据库中2009年1月1日至2013年12月31日的数据。我们的研究样本包括10343名患有ADHD的儿童和青少年,他们在2010年首次理赔前的360天内未服用新开具的药物。数据从2010年开始使用ADHD药物治疗时跟踪至2013年12月31日。在我们的样本中,4种ADHD药物的停药率范围为:速释哌甲酯为97.7%,托莫西汀为99.4%(使用超过30天的 refill gap);速释哌甲酯为56.7%,缓释哌甲酯为62.3%(使用超过60天的refill gap)。在停药数量方面,我们发现使用超过30天refill gap的药物之间存在显著差异。在4种ADHD药物中,缓释哌甲酯和托莫西汀的使用天数多于速释哌甲酯和渗透泵控释口服系统哌甲酯。在逻辑回归分析中,当使用超过30天的refill gap时,与速释哌甲酯组相比,缓释哌甲酯、渗透泵控释口服系统哌甲酯和托莫西汀的停药率较低。在依从性的逻辑回归分析中,我们未发现4种药物类型之间存在任何差异。我们建议应定期评估使用模式,以改善患有ADHD的儿童和青少年的未来治疗效果。